Fourth grade

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Retrieved on: 
Thursday, March 14, 2024
Bevacizumab, Ovarian cancer, Disease, Patient, Malignancy, Clinical trial, Fourth grade, Platinum, Thrombocytopenia, Food, Pharmaceutical industry

Fort Lee, NJ, March 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today announced preliminary data from the ongoing Phase 1b clinical trial of NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer, a deadly disease of unmet medical need. The NXP800 development program in this disease was granted Fast Track Designation by the U.S. Food and Drug Administration (“FDA”). The Phase 1b clinical trial is being conducted in top clinical centers in the United States and the United Kingdom.

Key Points: 
  • Fort Lee, NJ, March 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today announced preliminary data from the ongoing Phase 1b clinical trial of NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer, a deadly disease of unmet medical need.
  • The NXP800 development program in this disease was granted Fast Track Designation by the U.S. Food and Drug Administration (“FDA”).
  • The Phase 1b clinical trial is being conducted in top clinical centers in the United States and the United Kingdom.
  • Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, “We are pleased to share the preliminary results from the NXP800 Phase 1b study in the target patient population of platinum resistant, ARID1a-mutated ovarian cancer patients.

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Retrieved on: 
Saturday, December 9, 2023
Patient, Cogent, OLE, MAS, Deficit spending, ISM, GIST, Fourth grade, Poster, Bleeding, American Society of Hematology, APEX, Disease, KIT, MD Anderson Cancer Center, Society, Stromal cell, SSM, PD, ASH, Mutation, VAF, Hyperkinesia, Part, PGIC, Webcast, Safety, University, PEAK, Dermatology, Pharmaceutical industry

Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.

Key Points: 
  • Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.
  • Patients were enrolled with the following sub-types: 18 patients with indolent systemic mastocytosis (ISM) and two patients with smoldering systemic mastocytosis (SSM).
  • In patients with completed questionnaires:
    By week 12, bezuclastinib patients showed a median best improvement of 37% on MC-QoL vs. 24% for placebo patients.
  • Data from Part 1 of the Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) will be presented in a poster session at ASH on Monday, December 11, 2023 at ASH.

PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Well, Neck, Annual general meeting, DNA, Cervical cancer, Castration, ICI, PSA, ADC, Patient, Research, Lymph, E pluribus unum, Neoplasm, Cytokine, Cancer, Pembrolizumab, Oncology, Doctor of Philosophy, OS, Burtness, Webcast, Safety, Fourth grade, Food, Head, International, Radiation, PDS, Infection, Society, SOC, PDSB, KOL, Opinion, National Cancer Institute, IL12, Recurrence, CRT, CD8, Ferret, Nivolumab, Squamous-cell carcinoma, Biomarker, Standard works, HDAC, Clinical trial, NCI, FDA, Biotechnology, Vaccine, Prostate cancer, Immunotherapy, Survival, TH1, Prostate-specific antigen, Cetuximab, HPV, Docetaxel, Pharmaceutical industry, Medical imaging, Birth control, H1N1

The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.

Key Points: 
  • The Company will provide a business update on its conference call and webcast at 8:00 AM EST today.
  • PDS Biotech anticipates initiation of VERSATILE-003 in Q1 2024.
  • PDS Biotech’s cash balance as of September 30, 2023 was approximately $54.3 million.
  • PDS Biotech believes that, with initiating the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2024, its available cash resources will sustain operational and research and development endeavors into the third quarter of 2024.

Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Retrieved on: 
Sunday, October 22, 2023
MTD, Trial of the century, Plasma, Dana–Farber Cancer Institute, Half-life, Associate, ESMO, Progression-free survival, SERD, Congress, PFS, European Society for Medical Oncology, Circulating tumor DNA, Pharmacokinetics, ESR1, Division, Index, Webcast, Recurrence, Breast cancer, Oncology, CBR, Woman, ER, Fourth grade, Patient, Neoplasm, Fulvestrant, Recommended maximum intake of alcoholic beverages, Mutation, SAN, DNA, Road, Cryptocurrency, Pharmaceutical industry, Birth control

These results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

Key Points: 
  • These results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.
  • “These Phase 2 monotherapy study results demonstrate that palazestrant (OP-1250) has the potential to become a best-in-class endocrine therapy and improve upon current standard of care treatments for women living with metastatic breast cancer.
  • In addition to being well-tolerated, palazestrant has demonstrated compelling progression-free survival as monotherapy in a heavily pretreated patient population,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology.
  • A copy of the oral presentation is available on Olema’s website under the Science section of the Olema website.

PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer

Retrieved on: 
Wednesday, October 11, 2023
Doctor of Philosophy, SOC, Management of prostate cancer, Vaccine, Interleukin 10, Gamma ray, Trial of the century, Cell, Toxicity, Interleukin 12, Infection, International Cytokine & Interferon Society, Safety, National Cancer Institute, Early Prostate Cancer (clinical programme), Interim, Administration, Interleukin, TTY, Cytokine, Docetaxel, DLT, CD8, Head, Research, Clinical trial, Fourth grade, PSA, Bangladesh Technical Education Board, PDSB, Prostate cancer, Biotechnology, CD4, Patient, MD

Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301.

Key Points: 
  • Decrease in prostate specific antigen (PSA) levels was seen in all patients at all three tested doses of PDS0301.
  • Data to be presented by National Cancer Institute as an oral presentation at Cytokines 2023.
  • While all doses of PDS0301 were well-tolerated, the 12.0 mcg/kg dose of PDS0301 with chemotherapy provided the best combination of immune response and tolerability.
  • Interim data highlights to be presented at Cytokines 2023 include:
    All doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia.

Cursive handwriting is back in Ontario schools. Its success depends on at least 5 things

Retrieved on: 
Tuesday, July 11, 2023
Psychology, Learning, Handwriting, Alku, Stroke, Teaching, Grade 3, Curriculum, University, Printing, Research, Brain, Language, Fourth grade, Foundation, Movement, Ministry, Elementary, Student, Magnetic resonance imaging, Time, Manuscript, Child, Reading, Paper, Neuro, Letter, Achievement Medal, Hand, List, Nursing, Tutoring, Book, Typesetting, Education

It is a re-emphasis on direct instruction in foundational skills.

Key Points: 
  • It is a re-emphasis on direct instruction in foundational skills.
  • Handwriting is a learned skill and it must be taught through direct, explicit, programmatic, developmentally progressive, consistent and sustained instruction — it will not simply be “caught” incidentally.

How one writes connected to what one can say

    • He finds that a legible, fluent/fast script contributes significantly to the quality of text generated.
    • Research suggests this can impede their academic success as the demands for written literacy accelerate over time, beginning in Grade 4.

Research in neuro and cognitive sciences

    • The resurgence of handwriting comes with evolving research in the neuro and cognitive sciences that underscore its importance in its connection to learning to read and as a cognitive tool.
    • Researchers Daniel J. Plebanek and Karin H. James, experts in psychology and brain sciences, use functional magnetic resonance imaging to study brain activity.

Teaching handwriting has been marginalized

    • Teaching handwriting has long been marginalized in school curriculum, often trivialized as just an outdated skill.
    • Handwriting became crowded out by keyboarding and digital literacies associated with “21st century” learning goals and the shift to teaching “whole-language pedagogy” that emphasized context and meaning making, often at the expense of the underlying skills required to do so.
    • It’s no surprise, then, that in a study from the United States, few teachers report feeling prepared to teach handwriting.
    • This could involve a variety of printing and handwriting activities that are meaningful and purposeful for students.
    • While cursive has been undervalued and misunderstood for many years, there is a compelling case for cursive handwriting on the curriculum.

Young children’s words predict reading ability — 5 ways parents and caregivers can help grow them

Retrieved on: 
Monday, June 5, 2023
Fantasy, Cognition, Learning, Consciousness, Human, Magic, Vocabulary, Parent, Reading, First grade, Research, Recycling, Language, Fourth grade, Health policy, Literacy, Student, Running, Acquisition, Cooking, Child, Knowledge, Imagination, Eleventh grade, Book, Caregiver, Tutoring, Toy, Printing, Residential care, Risk management

Young learners must see and interact with combinations of letters and words thousands of times to support early reading fluency.

Key Points: 
  • Young learners must see and interact with combinations of letters and words thousands of times to support early reading fluency.
  • Young children are ready and capable of learning complex vocabulary (words like “construct,” for example) required as a knowledge base for reading proficiency as they mature, especially if taught strategically and explicitly.

Early childhood instruction

    • Early childhood instruction is critical to teach young children the crucial vocabulary they need from an early stage.
    • Yet research suggests the effectiveness of literacy instruction at the kindergarten level is mixed and uneven.

Early stages of reading

    • The early stages of learning to read, often described as decoding (using knowledge of the relationship of letters to sounds), can generally be attained by the vast majority of young learners by Grade 3.
    • This is achieved through instruction in phonemic awareness skills (noticing and working with specific sounds in spoken words), phonics (sound-letter relationships) and sight word recognition — perhaps 400 literate words.

Grade 4: Pivotal time

    • Grade 4 represents an enormous leap in literacy development because there’s a shift from early literacy learning associated with narrative texts to academic literacy learning associated with expository (informational) genres.
    • In Grade 4, academic vocabulary knowledge becomes the key predictor of whether young readers will be able to extract meaning from print on the page.
    • Literacy researchers Jeanne S. Chall and Vicki A. Jacobs coined the term “the Grade 4 slump” to describe the phenomenon of reading failure among so many young learners at this pivotal point.

Importance of early learning

    • Far too many young children do not make the transition successfully from apparent success with limited vocabulary requirements associated with early literacy benchmarks and later, more complex reading comprehension and capabilities.
    • Research from the United States finds some 33 per cent of Grade 4 students are unable to read at the basic level.

Mobilizing words

    • Here are some ways parents and caregivers can help children grow their words.
    • This means adults take the time to help children find the words they may be seeking, introduce and talk about new words and echo back and affirm children’s expanding vocabulary.
    • Provide opportunities for children to have tactile experiences, manipulating objects through hands-on play and helping around the house, providing the words for these objects.
    • For example, you might talk about recycling to help youngsters learn words such as dispose, separate, prevent and produce.
    • Draw attention to new words, teach the meanings and provide playful opportunities to learn and practise using them.

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress

Retrieved on: 
Thursday, May 11, 2023
Acute leukemia, CD19, Progression-free survival, CRS, Infection, B-cell maturation antigen, NHL, Cancer, HSCT, Fourth grade, PFS, ASCO, ORR, Congress, CAR, American Society of Clinical Oncology, Patient, B-ALL, Graceling, SAN, Cytokine release syndrome, Annual general meeting, EHA, Leukapheresis, Society, DL2, BCMA, Pharmaceutical industry, Medical device, Vaccine, Paint, RRMM

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, May 11, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that clinical data from three studies in B-NHL, RRMM and B-ALL will be presented at the 2023 European Hematology Association (EHA) Annual Meeting taking place June 8-15 in Frankfurt, Germany, and online. Clinical data from GC012F, the Company's FasTCAR-enabled autologous CAR-T cell therapy dual-targeting B-cell maturation antigen (BCMA) and CD19, in B-NHL (which was selected as an oral presentation) and RRMM, will also be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, and are currently under embargo until Thursday, May 25.

Key Points: 
  • The data showcases a 100% ORR and will be presented on Friday, June 9, 6:00 – 7:00 PM CEST.
  • At day 28 after infusion, 100% patients achieved minimal residual disease negative complete remission with/without incomplete count recovery (MRD- CR/CRi).
  • These data are currently under embargo and will publish on Thursday, May 25, concurrently with ASCO.
  • Details of the GC012F oral presentation in B-NHL are as follows:
    Details of the GC012F poster presentation in RRMM are as follows:
    For more information about the EHA2023 Congress, visit www.ehaweb.org .

Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives

Retrieved on: 
Tuesday, March 14, 2023
Safety, Fourth grade, Patient, CRS, Pharmaceutical industry

HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients.

Key Points: 
  • HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients.
  • The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid.
  • The company paused enrollment in its clinical studies and conducted a thorough review of the risk/benefit observed to date.
  • The Company is communicating with clinical trial sites and regulatory agencies regarding its decision to discontinue its trials, and an evaluation of the Company’s strategic alternatives is underway.

Lavras Gold launches Gold Trail in Rio Grande do Sul

Retrieved on: 
Thursday, February 23, 2023
LDS, Gold, Ouro, Curriculum, Fourth grade, Partnership, Child, Gold Trails and Ghost Towns, LGC, Rota, OTCQB, Mining, Uranium mining

TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- A cultural education program on the importance of gold mining to the development of the town of Lavras do Sul was launched earlier this month by Lavras do Sul Mineração (LDS Mineração), Lavras Gold Corp.’s (TSXV: LGC, OTCQB: LGCFF) Brazilian subsidiary.

Key Points: 
  • TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- A cultural education program on the importance of gold mining to the development of the town of Lavras do Sul was launched earlier this month by Lavras do Sul Mineração (LDS Mineração), Lavras Gold Corp.’s (TSXV: LGC, OTCQB: LGCFF) Brazilian subsidiary.
  • Developed in partnership with LDS Mineração, the Rota do Ouro, or Gold Trail, is a route with five stations that each highlight an aspect of gold mining history in the Lavras do Sul Community:
    Mineral Riches Station at the office of LDS Mineração.
  • Children will visit twice, once each semester, coinciding with when the curriculum covers the town’s history.
  • “We want this to be an interactive experience,” said Paulo Serpa, Lavras Gold’s Country Manager.